Transposagen and TransGenic strike knockout deal for Japan
This article was originally published in Scrip
Executive Summary
Transposagen Biopharmaceuticals, a US provider of knockout rats for genomic pharmaceutical research, has entered the Japanese market through a deal with TransGenic. The Japanese firm, which already supplies its own knockout mice, will market Transposagen's lines under a non-exclusive agreement. The animals are missing selected genes and are used widely as disease models in corporate and academic preclinical research. TransGenic has other similar deals with Deltagen of the US and Austria's JSW-Research.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: CAR-Ts and malignancies; comeback for GSK’s Blenrep?; Novartis’s pipeline cull; FGF21 analogs in NASH; and a call to action from the Scrip Awards Lifetime Achievement winner.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?